RT Journal Article
SR Electronic
T1 Alzheimer’s Disease Sequencing Project Release 4 Whole Genome Sequencing Dataset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.03.24317000
DO 10.1101/2024.12.03.24317000
A1 Leung, Yuk Yee
A1 Lee, Wan-Ping
A1 Kuzma, Amanda B
A1 Nicaretta, Heather
A1 Valladares, Otto
A1 Gangadharan, Prabhakaran
A1 Qu, Liming
A1 Zhao, Yi
A1 Ren, Youli
A1 Cheng, Po-Liang
A1 Kuksa, Pavel P
A1 Wang, Hui
A1 White, Heather
A1 Katanic, Zivadin
A1 Bass, Lauren
A1 Saravanan, Naveen
A1 Greenfest-Allen, Emily
A1 Kirsch, Maureen
A1 Cantwell, Laura
A1 Iqbal, Taha
A1 Wheeler, Nicholas R
A1 Farrell, John J.
A1 Zhu, Congcong
A1 Turner, Shannon L
A1 Gunasekaran, Tamil I
A1 Mena, Pedro R
A1 Jin, Jimmy
A1 Carter, Luke
A1 Alzheimer’s Disease Sequencing Project
A1 Zhang, Xiaoling
A1 Vardarajan, Badri N
A1 Toga, Arthur
A1 Cuccaro, Michael
A1 Hohman, Timothy J
A1 Bush, William S
A1 Naj, Adam C
A1 Martin, Eden
A1 Dalgard, Clifton
A1 Kunkle, Brian W
A1 Farrer, Lindsay A
A1 Mayeux, Richard P
A1 Haines, Jonathan L
A1 Pericak-Vance, Margaret A
A1 Schellenberg, Gerard D
A1 Wang, Li-San
YR 2024
UL http://medrxiv.org/content/early/2024/12/06/2024.12.03.24317000.abstract
AB The Alzheimer’s Disease Sequencing Project (ADSP) is a national initiative to understand the genetic architecture of Alzheimer’s Disease and Related Dementias (AD/ADRD) by sequencing whole genomes of affected participants and age-matched cognitive controls from diverse populations. The Genome Center for Alzheimer’s Disease (GCAD) processed whole-genome sequencing data from 36,361 ADSP participants, including 35,014 genetically unique participants of which 45% are from non-European ancestry, across 17 cohorts in 14 countries in this fourth release (R4). This sequencing effort identified 387 million bi-allelic variants, 42 million short insertions/deletions, and 2.2 million structural variants. Annotations and quality control data are available for all variants and samples. Additionally, detailed phenotypes from 15,927 participants across 10 domains are also provided. A linkage disequilibrium panel was created using unrelated AD cases and controls. Researchers can access and analyze the genetic data via NIAGADS Data Sharing Service, the VariXam tool, or NIAGADS GenomicsDB.Competing Interest StatementTimothy Hohman serves in the Scientific Advisory Board for Vivid Genomics, and Deputy Editor for Alzheimer's & Dementia: TRCI.Funding StatementData for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging. Details of the funding statement is available at the end of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In this manuscript, all data are from NIAGADS. NIAGADS contains both individual level and aggregated/summary data. All individual level data has been de-identified and NIAGADS users are prohibited from trying to reidentify individuals as part of the code of conduct they sign when applying for data within NIAGADS. Open-access data can be freely downloaded from the NIAGADS website. Restricted-access data are available through the NIAGADS Data Sharing Service (dss.niagads.org) and require an approved data access request to ensure compliance with privacy and ethical guidelines and in accordance with the terms outlined by the submitting Institutional Review Boards (IRBs) and the consent provided by research participants. For detailed instructions on accessing specific datasets, including open and restricted data, please visit the NIAGADS website at www.niagads.orgI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data described are available at https://dss.niagads.org/. VariXam is accessible at https://varixam.niagads.org/. GenomicsDB is accessible at https://www.niagads.org/genomics/app.